Novavax Inc (NVAX)

[TRUISM]

Novavax, Inc. Price Target Update
By Adam Porter - May 15, 2015
Click For Link

Novavax, Inc. (NASDAQ:NVAX) should head towards $10.66 per share according to 5 Analysts in consensus. However, if the road gets shaky, the stock may fall short to $10 per share. The higher price estimate target is at $12 according to the Analysts.

Shares have received recommendation from many analysts. As many as 5 brokerage firms have rated Novavax Inc (NASDAQ:NVAX) at 1. Research Analysts at Zacks have ranked the company at 2, suggesting the traders with a rating of buy for the short term. 5 analysts rated the company as a strong buy.

Novavax, Inc. (NASDAQ:NVAX) rose 1.89% or 0.16 points on Thursday and made its way into the gainers of the day. After trading began at $8.52 the stock was seen hitting $8.74 as a peak level and $8.28 as the lowest level. The stock ended up at $8.63. The daily volume was measured at 2,373,014 shares. The 52-week high of the share price is $9.95 and the 52-week low is $3.92. The company has a market cap of $2,313 million.

Novavax, Inc. (Novavax) is a clinical stage biopharmaceutical company. The Company focuses on developing recombinant vaccines. The Companys technology platform is based on recombinant vaccine technology that includes the virus-like particles (VLPs). The Companys vaccine candidates are genetically engineered three-dimensional nanostructures, which incorporate immunologically important recombinant proteins. In July 2013, Novavax acquired approximately 97.4% of shares in Isconova AB.



Blessings to All

TRUTH